CY1114520T1 - Παραγωγο ινδολιζινης και χρηση αυτου για ιατρικους σκοπους - Google Patents
Παραγωγο ινδολιζινης και χρηση αυτου για ιατρικους σκοπουςInfo
- Publication number
- CY1114520T1 CY1114520T1 CY20131100921T CY131100921T CY1114520T1 CY 1114520 T1 CY1114520 T1 CY 1114520T1 CY 20131100921 T CY20131100921 T CY 20131100921T CY 131100921 T CY131100921 T CY 131100921T CY 1114520 T1 CY1114520 T1 CY 1114520T1
- Authority
- CY
- Cyprus
- Prior art keywords
- group
- fluorine atom
- atom
- prophylactic
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Αποκαλύπτεται μια ένωση χρήσιμη ως προφυλακτικός ή θεραπευτικός παράγων για ασθένειες που σχετίζονται με την ανωμαλία των επιπέδων ουρικού οξέος στον ορό και άλλες ασθένειες. Ειδικά αποκαλύπτονται: παράγωγο ινδολιζίνης που αντιπροσωπεύεται από τον τύπο (Ι) ή προφάρμακο ή άλας αυτού, που έχει ανασταλτική δραστικότητα επί οξειδάσης ξανθίνης και είναι χρήσιμο ως προφυλακτικός ή θεραπευτικός παράγων για ασθένειες που σχετίζονται με την ανωμαλία επιπέδων ουρικού οξέος ορού και άλλες. Στον τύπο, ο δακτύλιος U αντιπροσωπεύει αρύλ ομάδα ή ετεροαρύλ ομάδα, το R1 αντιπροσωπεύει άτομο αλογόνου, υδρόξυ ομάδα ή τις παρόμοιες, το R2 αντιπροσωπεύει άτομο αλογόνου, υδρόξυ ομάδα, αλκύλ ομάδα, αλκόξυ ομάδα, αλκύλ ομάδα υποκατεστημένη με άτομο φθορίου, αλκόξυ ομάδα υποκατεστημένη με άτομο φθορίου ή τις παρόμοιες, το m αντιπροσωπεύει 0 έως 2 το n αντιπροσωπεύει 0 έως 3 και το R3 αντιπροσωπεύει άτομο υδρογόνου, άτομο φθορίου ή τα παρόμοια.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009086306 | 2009-03-31 | ||
| JP2009279976 | 2009-12-10 | ||
| EP10758713.1A EP2415771B1 (en) | 2009-03-31 | 2010-03-30 | Indolizine derivative and use thereof for medical purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114520T1 true CY1114520T1 (el) | 2016-10-05 |
Family
ID=42828231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100921T CY1114520T1 (el) | 2009-03-31 | 2013-10-17 | Παραγωγο ινδολιζινης και χρηση αυτου για ιατρικους σκοπους |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8748452B2 (el) |
| EP (1) | EP2415771B1 (el) |
| JP (1) | JP5638513B2 (el) |
| KR (1) | KR101772963B1 (el) |
| CN (1) | CN102365281B (el) |
| AU (1) | AU2010231615B2 (el) |
| BR (1) | BRPI1013432B1 (el) |
| CA (1) | CA2755132C (el) |
| CY (1) | CY1114520T1 (el) |
| DK (1) | DK2415771T3 (el) |
| ES (1) | ES2429148T3 (el) |
| HK (1) | HK1165793A1 (el) |
| HR (1) | HRP20130846T1 (el) |
| MX (1) | MX2011010395A (el) |
| PL (1) | PL2415771T3 (el) |
| PT (1) | PT2415771E (el) |
| RU (1) | RU2529868C2 (el) |
| SI (1) | SI2415771T1 (el) |
| TW (1) | TWI471325B (el) |
| WO (1) | WO2010113942A1 (el) |
| ZA (1) | ZA201107085B (el) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2623505B1 (en) * | 2010-09-29 | 2015-07-29 | Kissei Pharmaceutical Co., Ltd. | (aza)indolizine derivatives as xanthine oxidase inhibitors |
| NO2686520T3 (el) | 2011-06-06 | 2018-03-17 | ||
| WO2013027801A1 (ja) | 2011-08-24 | 2013-02-28 | キッセイ薬品工業株式会社 | 縮合へテロ環誘導体及びその医薬用途 |
| CN104981242A (zh) | 2012-10-23 | 2015-10-14 | 帝人制药株式会社 | 肿瘤溶解综合征的治疗药和预防药 |
| MX2015016494A (es) * | 2013-05-31 | 2016-11-18 | Takeda Pharmaceuticals Usa Inc | Métodos de tratamiento y composiciones con inhibidores de xantina oxidasa. |
| US11857543B2 (en) | 2013-06-13 | 2024-01-02 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| ES2672797T3 (es) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Ciclopropilaminas como inhibidores de LSD1 |
| HUE045725T2 (hu) | 2014-02-13 | 2020-01-28 | Incyte Corp | Ciklopropilaminok mint LSD1 inhibitorok |
| ES2760261T3 (es) | 2014-02-13 | 2020-05-13 | Incyte Corp | Ciclopropilaminas como inhibidores de LSD1 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| JP2018502882A (ja) | 2015-01-23 | 2018-02-01 | アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ２−（５−（３−フルオロフェニル）−３−ヒドロキシピコリンアミド）酢酸の固体形態、その組成物及び使用 |
| MX2017012460A (es) | 2015-04-01 | 2018-01-30 | Akebia Therapeutics Inc | Composiciones y metodos para el tratamiento de la anemia. |
| MX2017012699A (es) | 2015-04-03 | 2018-02-09 | Incyte Corp | Compuestos heterociclicos como inhibidores de demetilasa 1 especifica de lisina (lsd1). |
| KR20180051523A (ko) | 2015-08-12 | 2018-05-16 | 인사이트 코포레이션 | Lsd1 저해제의 염 |
| DK3344604T3 (da) | 2015-09-02 | 2020-12-07 | Sunshine Lake Pharma Co Ltd | Carboxy-substituerede (hetero) aromatiske ringderivater og fremstillingsfremgangsmåde og anvendelser deraf |
| KR20180112773A (ko) * | 2015-12-28 | 2018-10-12 | 상하이 포천 파마슈티컬 씨오 엘티디 | 인돌리진 유도체, 조성물 및 사용 방법 |
| SG11201809299QA (en) | 2016-04-22 | 2018-11-29 | Incyte Corp | Formulations of an lsd1 inhibitor |
| JP6816287B2 (ja) * | 2016-09-07 | 2021-01-20 | シャンハイ ハイヘ ファーマシューティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｈｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ | ピリジン並びに５員芳香環系化合物、その製造方法及び使用 |
| TWI822776B (zh) | 2018-05-09 | 2023-11-21 | 美商阿克比治療有限公司 | 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| JP2023052711A (ja) * | 2020-03-04 | 2023-04-12 | 国立研究開発法人理化学研究所 | 化合物を放出する方法 |
| AR126164A1 (es) * | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
| CN115785018A (zh) * | 2022-12-26 | 2023-03-14 | 湖北广济药业股份有限公司 | 一种非布司他脱羧杂质的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ193926A (en) * | 1979-07-06 | 1984-05-31 | Labaz Sanofi Nv | 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines |
| FR2779724B1 (fr) * | 1998-06-10 | 2001-04-20 | Rhone Poulenc Rorer Sa | Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent |
| DE602006018635D1 (de) * | 2005-10-07 | 2011-01-13 | Astellas Pharma Inc | Triarylcarbonsäurederivat |
| US7947707B2 (en) | 2005-10-07 | 2011-05-24 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| AU2008239018B2 (en) | 2007-04-11 | 2013-09-05 | Kissei Pharmaceutical Co., Ltd. | 5-membered heterocyclic derivative and use thereof for medical purposes |
| EP2133332B1 (en) | 2007-04-11 | 2013-09-18 | Kissei Pharmaceutical Co., Ltd. | (aza)indole derivative and use thereof for medical purposes |
| JP5330990B2 (ja) | 2007-04-11 | 2013-10-30 | キッセイ薬品工業株式会社 | 含窒素複素環化合物およびそれを含有する医薬組成物 |
-
2010
- 2010-03-30 MX MX2011010395A patent/MX2011010395A/es active IP Right Grant
- 2010-03-30 KR KR1020117024420A patent/KR101772963B1/ko active IP Right Grant
- 2010-03-30 BR BRPI1013432A patent/BRPI1013432B1/pt not_active IP Right Cessation
- 2010-03-30 PT PT107587131T patent/PT2415771E/pt unknown
- 2010-03-30 SI SI201030404T patent/SI2415771T1/sl unknown
- 2010-03-30 US US13/259,621 patent/US8748452B2/en active Active
- 2010-03-30 RU RU2011143741/04A patent/RU2529868C2/ru not_active IP Right Cessation
- 2010-03-30 CA CA2755132A patent/CA2755132C/en not_active Expired - Fee Related
- 2010-03-30 WO PCT/JP2010/055692 patent/WO2010113942A1/ja active Application Filing
- 2010-03-30 ES ES10758713T patent/ES2429148T3/es active Active
- 2010-03-30 PL PL10758713T patent/PL2415771T3/pl unknown
- 2010-03-30 AU AU2010231615A patent/AU2010231615B2/en not_active Ceased
- 2010-03-30 CN CN201080014876.1A patent/CN102365281B/zh active Active
- 2010-03-30 JP JP2011507210A patent/JP5638513B2/ja active Active
- 2010-03-30 EP EP10758713.1A patent/EP2415771B1/en active Active
- 2010-03-30 DK DK10758713.1T patent/DK2415771T3/da active
- 2010-03-31 TW TW99109853A patent/TWI471325B/zh not_active IP Right Cessation
-
2011
- 2011-09-28 ZA ZA2011/07085A patent/ZA201107085B/en unknown
-
2012
- 2012-06-29 HK HK12106395.4A patent/HK1165793A1/xx not_active IP Right Cessation
-
2013
- 2013-09-10 HR HRP20130846AT patent/HRP20130846T1/hr unknown
- 2013-10-17 CY CY20131100921T patent/CY1114520T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2429148T3 (es) | 2013-11-13 |
| EP2415771B1 (en) | 2013-07-31 |
| PT2415771E (pt) | 2013-10-03 |
| JPWO2010113942A1 (ja) | 2012-10-11 |
| DK2415771T3 (da) | 2013-10-14 |
| EP2415771A1 (en) | 2012-02-08 |
| CN102365281B (zh) | 2014-11-12 |
| ZA201107085B (en) | 2012-12-27 |
| TW201040178A (en) | 2010-11-16 |
| TWI471325B (zh) | 2015-02-01 |
| EP2415771A4 (en) | 2012-08-29 |
| WO2010113942A1 (ja) | 2010-10-07 |
| MX2011010395A (es) | 2011-10-24 |
| CA2755132C (en) | 2018-02-13 |
| US8748452B2 (en) | 2014-06-10 |
| AU2010231615B2 (en) | 2014-05-15 |
| JP5638513B2 (ja) | 2014-12-10 |
| CN102365281A (zh) | 2012-02-29 |
| RU2011143741A (ru) | 2013-05-10 |
| CA2755132A1 (en) | 2010-10-07 |
| SI2415771T1 (sl) | 2013-12-31 |
| KR101772963B1 (ko) | 2017-08-31 |
| PL2415771T3 (pl) | 2014-01-31 |
| RU2529868C2 (ru) | 2014-10-10 |
| HK1165793A1 (en) | 2012-10-12 |
| BRPI1013432A2 (pt) | 2016-04-05 |
| KR20110132599A (ko) | 2011-12-08 |
| US20120015972A1 (en) | 2012-01-19 |
| BRPI1013432B1 (pt) | 2019-12-17 |
| AU2010231615A1 (en) | 2011-11-03 |
| HRP20130846T1 (hr) | 2013-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114520T1 (el) | Παραγωγο ινδολιζινης και χρηση αυτου για ιατρικους σκοπους | |
| CY1121231T1 (el) | Παραγωγο τετραϋδροϊμιδαζο[1,5-d][1,4]οξαζεπινης | |
| CY1120073T1 (el) | Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2 | |
| MX2009010491A (es) | Derivado heterociclico de 5 miembros y su uso para propositos medicos. | |
| CY1115533T1 (el) | Παραγωγα χολικου οξεος ως προσδετες fxr για την προληψη ή τη θεραπευτικη αγωγη νοσηματων ή καταστασεων οι οποιες προκαλουνται με τη μεσολαβηση fxr | |
| CY1118862T1 (el) | Νεα δικυκλικη ετεροκυκλικη ενωση | |
| NZ601121A (en) | 5-alkynyl-pyrimidines | |
| MX337527B (es) | Derivado de (aza)indol y su uso para propositos medicos. | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| CY1118390T1 (el) | Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου | |
| MA32604B1 (fr) | Composes organiques | |
| WO2009156861A8 (en) | Substituted pyrimidone derivatives | |
| MX2012015023A (es) | Derivado novedoso de nicotinamida o sal del mismo. | |
| NZ601483A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
| MX2013001614A (es) | Compuestos heterociclico. | |
| NZ594195A (en) | N-acyl anthranilic acid derivative or salt thereof | |
| CY1113649T1 (el) | Θεραπευτικα μεσα | |
| WO2008108386A1 (ja) | 医薬組成物 | |
| NI201000107A (es) | Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa. | |
| UA105786C2 (uk) | Адитивні солі амінів, що містять гідроксильні і/або карбоксильні групи, з похідними амінонікотинової кислоти як інгібітори dhodh | |
| MX348860B (es) | Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa. | |
| MX2012002528A (es) | Agente terapeutico para trastornos del estado de animo. | |
| ATE492534T1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| CY1112638T1 (el) | Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον |